Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 28 clinical trials
Prospective Monocentric Clinical-biological Database (BCBPancréas)

) derived tumors of patients reported that the response rate of PDX to certain drugs (gemcitabine, erlotinib ...) used clinically was similar to the response rates of patients enrolled in clinical studies

adenocarcinoma
cancer chemotherapy
tumor cells
erlotinib
gemcitabine
  • 1 views
  • 20 Feb, 2022
  • 1 location
Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma

(of sunitinib, brivanib, linifanib, and erlotinib plus sorafenib) that did not show non-inferiority. Sorafenib, an oral multikinase inhibitor, has been the only systemic therapy demonstrated to

  • 0 views
  • 02 Jun, 2022
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

The purpose of this study is to evaluate the efficacy and feasibility of combination chemotherapy with target agents according to the result of targeted deep sequencing in pediatric patients with relapsed/refractory solid tumor or AML.

etoposide
cytarabine
imatinib
ifosfamide
cancer
  • 0 views
  • 24 Jan, 2021
  • 1 location
Assessment of Gastric pH Changes Induced by Ascorbic Acid Tablets

This study evaluates the use of ascorbic acid, vitamin C, to temporary reduce gastric pH in individuals with omeprazole induced hypochlorhydia. All participants will receive ascorbic acid tablets to measure the change in gastric pH.

Accepts healthy volunteers
  • 0 views
  • 24 Apr, 2022
  • 1 location
Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI.

This is an open-label, single-intervention, multicenter clinical trial in patients with non-small cell lung cancer with asymptomatic or mildly symptomatic brain metastases after failure of EGFR TKI treatment. The objective of this study is as follows. Primary objective : intracranial objective response rate (iORR) with RECIST 1.1 Secondary objectives : …

lung cancer
measurable disease
lung carcinoma
afatinib
EGFR
  • 0 views
  • 06 May, 2022
  • 5 locations
Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study (ROSE)

Study Objectives are: To assess the safety of osimertinib treatment continuation during irradiation therapy for palliation or oligoprogressive disease by assessment of grade 3-5 AEs during and after concomitant osimertinib and irradiation of tumor sites. To assess the efficacy of osimertinib treatment continuation during irradiation therapy for palliation or oligoprogressive …

  • 0 views
  • 06 Jun, 2022
  • 1 location
Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

The best drug sequencing of dacomitinib or osimertinib in patients with advanced or metastatic Epidermal Growth Factor Receptor (EGFR) mutation positive non-small-cell lung cancer (NSCLC) has not yet been determined. The study enables investigation of the efficacy of dacomitinib followed by or subsequent to osimertinib osimertinib in patients with classical …

  • 0 views
  • 13 May, 2021
  • 20 locations
Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.

This single-arm, open, multicenter clinical study is going to evaluate the efficacy and safety of combination therapy with ectiecinib, pemetrexed and platinum in patients with metastatic non-squamous non-small cell lung cancer with EGFR mutations who did not progress after pemetrexed in combination with platinum-based chemotherapy.

metastasis
squamous non-small cell lung carcinoma
inulin clearance
measurable disease
platinum-based chemotherapy
  • 0 views
  • 10 Feb, 2022
  • 1 location
Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) (STEREO)

STEREO is single-arm phase II study, which aims to evaluate the safety and efficacy of osimertinib combined with early locally ablative radiotherapy of all cancer sites in patients with synchronous oligo-metastatic (primary tumour and maximum 5 metastases) EGFR-mutant (exon 19 deletion or exon 21 L858R) NSCLC. Eradication of all macroscopic …

  • 0 views
  • 18 Apr, 2022
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients

The aim of this study is to evaluate the safety and effectiveness of Fruquintinib combined with Albumin Paclitaxel and Gemcitabine on pancreatic cancer patients with liver metastases. Plan to enrollment 30 patients.

metastatic pancreatic cancer
measurable disease
gemcitabine
neutrophil count
paclitaxel
  • 0 views
  • 25 Mar, 2022